SCHEMBL460754

SCHEMBL460754

Oc1ccccc1CNCc1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 1.00
CYP2D6 P10635 1/20 1.00
HIF1A Q16665 1/20 1.00
CA12 O43570 6/20 0.82
CA2 P00918 6/20 0.82
PKM P14618 1/20 0.76
CA9 Q16790 5/20 0.75
KDM4E B2RXH2 1/20 0.75
HSD17B10 Q99714 1/20 0.75
MPO P05164 8/20 0.72
SLC6A4 P31645 1/20 0.67
HSPA5 P11021 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2794849 0.90 CA12 (1.00) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL31532322 0.90 CA12 (1.00) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL12083246 0.90 TSHR (0.82) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL6435315 0.89 PKM (0.96) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL7930135 0.88 TSHR (0.78) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL30586214 0.88 CA12 (0.95) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL14354016 0.88 CA12 (0.95) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL30586212 0.88 CA12 (0.95) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL30197711 0.88 CA12 (0.95) TSHRCYP2D6HIF1ACA12CA2
SCHEMBL30586211 0.88 CA12 (0.95) TSHRCYP2D6HIF1ACA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115073309-A Preparation method of o-hydroxybenzylamine 苏州敬业医药化工有限公司 2022-09-20 CN claimed
CN-109223579-B Dental restoration material and preparation method thereof 张庆鹏 2021-04-13 CN claimed
EP-2797934-B1 CATALYST COMPOSITIONS CONTAINING N,N-BIS[2-HYDROXIDEBENZYL]AMINE TRANSITION METAL COMPOUNDS FOR THE POLYMERIZATION OF OLEFINS CHEVRON PHILLIPS CHEMICAL CO (US) 2016-08-03 EP claimed
US-9115225-B2 Catalyst systems for production of alpha olefin oligomers and polymers CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2015-08-25 US claimed
US-8987394-B2 Catalyst compositions for the polymerization of olefins CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2015-03-24 US claimed
EP-2797934-A1 CATALYST COMPOSITIONS CONTAINING N, N-BIS [2-HYDROXIDEBENZYL]AMINE TRANSITION METAL COMPOUNDS FOR THE POLYMERIZATION OF OLEFINS Chevron Phillips Chemical Company LP (US) 2014-11-05 EP claimed
US-20140296456-A1 Catalyst Systems for Production of Alpha Olefin Oligomers and Polymers CHEVRON PHILLIPS CHEMICAL COMPANY LP 2014-10-02 US claimed
US-20140296453-A1 Catalyst Compositions for the Polymerization of Olefins CHEVRON PHILLIPS CHEMICAL COMPANY LP 2014-10-02 US claimed
US-8791217-B2 Catalyst systems for production of alpha olefin oligomers and polymers CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2014-07-29 US claimed
US-8785576-B2 Catalyst compositions for the polymerization of olefins CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2014-07-22 US claimed
US-20130172497-A1 CATALYST COMPOSITIONS FOR THE POLYMERIZATION OF OLEFINS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 US claimed
WO-2013101478-A1 CATALYST SYSTEMS FOR PRODUCTION OF ALPHA OLEFIN OLIGOMERS AND POLYMERS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 WO claimed
US-20130172498-A1 CATALYST SYSTEMS FOR PRODUCTION OF ALPHA OLEFIN OLIGOMERS AND POLYMERS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 US claimed
WO-2013101476-A1 CATALYST COMPOSITIONS CONTAINING N, N-BIS [2-HYDROXIDEBENZYL] AMINE TRANSITION METAL COMPOUNDS FOR THE POLYMERIZATION OF OLEFINS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 WO claimed
EP-2349995-A1 SELECTIVE SEPRASE INHIBITORS Molecular Insight Pharmaceuticals, Inc. (US) 2011-08-03 EP claimed
US-20100098633-A1 SELECTIVE SEPRASE INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2010-04-22 US claimed
WO-2010036814-A1 SELECTIVE SEPRASE INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2010-04-01 WO claimed
CN-109415468-B Electro-optical polymers 国立研究开发法人情报通信研究机构 2024-06-07 CN disclosed
WO-2001005741-A1 METHOD FOR PRODUCING AMINES BY HOMOGENEOUSLY CATALYZED REDUCTIVE AMINATION OF CARBONYL COMPOUNDS DEGUSSA AG (DE) 2001-01-25 WO disclosed
US-4748276-A Process for preparing N,N-bis(2-hydroxyethyl)benzylamine and N,N-bis(2-chloroethyl)benzylamine STERLING DRUG INC. (US) 1988-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172497-A1 CATALYST COMPOSITIONS FOR THE POLYMERIZATION OF OLEFINS AOC2, HMBS, NIT2 TSHR 4868/4885CYP2D6 1110/4885HIF1A 3076/4885
US-20100098633-A1 SELECTIVE SEPRASE INHIBITORS SLC6A7, DNPEP, PREP TSHR 2864/4885CYP2D6 4523/4885HIF1A 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.